These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29570693)

  • 1. Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease.
    Menéndez-González M; Padilla-Zambrano HS; Tomás-Zapico C; García BF
    Brain Sci; 2018 Mar; 8(4):. PubMed ID: 29570693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.
    Lee HJ; Bae EJ; Lee SJ
    Nat Rev Neurol; 2014 Feb; 10(2):92-8. PubMed ID: 24468877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
    Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
    Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.
    Lee SJ
    J Mol Neurosci; 2008; 34(1):17-22. PubMed ID: 18157654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease.
    Murakami H; Ono K; Shiraishi T; Umehara T; Omoto S; Iguchi Y
    Front Aging Neurosci; 2020; 12():616357. PubMed ID: 33551789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease.
    Bates CA; Zheng W
    Fluids Barriers CNS; 2014; 11():17. PubMed ID: 25093076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
    Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
    Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.